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between 123I-MIBG imaging and cardiopulmonary exercise testing
(CPET) parameters in HFpEF.
The patients were recruited through a clinical screening. Eligi-
bility criteria involved age ≥ 18 years, signs and symptoms of HF
[1], LVEF N50% with evidence of diastolic dysfunction by echocardi-
ography [9]: HFpEF was diagnosed if tissue Doppler E/E’ N 15; if E/E’
ratio 15 N E/E′ N 8, additional investigation is required (ex: left atrial
volume index N40 ml/m2 or E/A b 0.5); and if E/E′ b 8, the patient
was not included. We excluded diabetes, atrial ﬁbrillation, pace-
maker and any conditions that contraindicate CPET. Eligible pa-Heart failure (HF) can be classiﬁed into HF with reduced ejection
fraction (HFrEF), when the main altered mechanism is myocardial
contractility or HF with preserved ejection fraction (HFpEF), when
the diastolic dysfunction is the main mechanism [1]. However, both
the substrates can be present in the same patient and the standard
treatment probably should be used despite the lack of mortality
data [1].
Sympathetic nervous system activation plays an important role
in the progression of HF and cardiac imaging with iodine-123
metaiodobenzylguanidine (123I-MIBG) was developed to visualize
sympathetic innervation and was used to study myocardial adrener-
gic nerve activity [2]. The early and late heart-to-mediastinum ratio
(H/M) can evaluate the integrity and function of the nervous termi-
nal and the washout rate (WR) may reﬂect the adrenergic activity
[3]. Few studies [4,5] have demonstrated that 123I-MIBG imaging
was independently associated with an increased risk for cardiac
events in HFpEF.
HFpEF patients have been characterized by an impaired peak oxygen
consumption (VO2) [6–8] and a steep slope of the relationship between
minute ventilation and carbon dioxide production (VE/VCO2 slope) [8].
The relationship between adrenergic activity and exercise parameters.in HFpEF is unknown. Our purpose was to evaluate the association
tients provided a consent form after receiving verbal and written
details regarding the procedures adopted in the study, which was
approved by the Ethics Committee of our institution.
Subjects underwent 123I-MIBG imaging acquired 30 min and
4 h after 5 mCi 123I-MIBG administration. We evaluated the sym-
pathetic neuronal integrity, quantiﬁed by the early and late H/M
[2–5]. Sympathetic activation was estimated by WR [2–5]. All pa-
tients performed a symptom-limited treadmill CPET using ramp
protocols. Peak VO2 was measured with commercially available
metabolic carts (MedGraphics VO2000, Brazil) and was deﬁned as
the highest VO2 during the last 30 s of exercise [2,7,8]. VE/VCO2
slope was calculated using the spreadsheet software package [8].
Standard 12-lead ECGs, blood pressure systolic (SBP) and heart
rate (HR) were obtained at rest, each minute during exercise and
recovery. The HR reserve was determined by the method of
Kallistratos et al. [10]. The HR recovery (HRR) was deﬁned by the
method of Phan et al. [6].
Data are presented as median, interquartile range and percentage.
Spearman coefﬁcient was used as univariate analysis and stepwise
linear regression as multivariate analysis. Statistical signiﬁcance was
accepted at the 0.05 level.
Twenty-ﬁve patients were evaluated in the present study. Base-
line characteristics, results of echocardiography, exercise testing
and 123I-MIBG imaging are shown in Table 1. By univariate analysis,
there was a negative correlation between the early (r = −0.463,
p = 0.02) and late H/M (r = −0.486, p = 0.014) with the VE/VCO2
slope. The Peak VO2 presented positive correlation between with the
late H/M (r = 0.452, p = 0.023) and negative with WR (r =−0.449,
Table 1
Baseline characteristics, 123I MIBG imaging and CPET parameters.
Variables
N= 25
Age 57 (52–67) years
Female 76%
Hypertensive etiology 92%
Echocardiogram
LVEF 64 (60.5–71.5) %
LAVI 44.6 (40.49–48.1) ml/m2
E/E′ 16 (14.45–17)
E/A 0.39 (0.28–0.6)
LVMI 124 (110–129.85) g/m2
Medications
Beta-blocker 52%
ACEI 84%
Hydralazine 16%
Nitrate 24%
Spironolactone 20%
Diuretic 64%
Early H/M 1.80 (1.58–1.94)
Late H/M 1.65 (1.48–1.96)
WR 29 (19.7–38.5) %
Rest SBP 152 (143–170) mmHg
Rest DBP 90 (78–104) mmHg
Rest HR 72 (63–82) bpm
Peak SBP 232 (217–246) mmHg
Peak HR 121 (110.5–143.5) bpm
Δ SBP 72 (58–99) mmHg
HR reserve 59.79 (42.77–83.44) %
HRR 1st minute 12 (5–19) bpm
HRR 2nd minute 19 (14–31.5) bpm
Peak VO2 12.75 (10.13–17.19 ml.(kg·min)−1
VE/VCO2 slope 23.37 (21.14–26.79)
LVEF: left ventricular ejection fraction; LAVI: left atrial volume index; E/E’: ratio of
early mitral diastolic inﬂow velocity to early diastolic mitral annular velocity; E/A:
ratio of early to late mitral inﬂow velocities; LVMI: left ventricular mass index;
ACEI: Angiotensin converting enzyme inhibitors; H/M: the heart/mediastinum
uptake ratio; WR: washout rate; SBP: Systolic blood pressure; DBP: Diastolic
blood pressure; HR: heart rate; Δ SBP: variation in systolic blood pressure during
exercise; HRR: heart rate recovery; VO2: oxygen consumption; VE/VCO2 slope: a
steep slope of the relationship between minute ventilation and carbon dioxide
production.
Fig. 1. Linear regression 123I-MIBG wa
901Correspondencep = 0.024). WR had negative correlation with peak HR (r =−0.465,
p = 0.019) and HR reserve (r =−0.553, p = 0.004). Other variables
such as peak and variation of SBP and HRR did not demonstrate signif-
icant correlation with other parameters.
Using multivariate analysis, we observed that the VE/VCO2 slope
was the variable that was best associated with late H/M (r2 = 0.236,
p = 0.011), and the HR reserve with WR (r2 = 0.375, p = 0.001), as
shown in Fig. 1. The presence of the variable “beta-blockers users” had
no inﬂuence on our results (late H/M p= 0.1; WR p= 0.4; peak VO2:
r2 = 0.386 p= 0.8).
We observed an association between CPET parameters with the
123I-MIBG imaging in HFpEF. The intensity in cardiac adrenergic
innervation abnormalities was associated with the degree of car-
diovascular impairment during exercise. Katoh et al. [4] reported
that lower late H/M and higher WR were associated with worse
prognosis. The WR was the best predictor of adverse events in
their study. We found WR values within the group of higher risk
of events according to the authors' data [4]. These data, associated
with low peak VO2, confer to these patients additional risk of
adverse events, demonstrating the need for optimal medical treat-
ment. Sugiura et al. [5] reported that 123I-MIBG imaging parame-
ters were correlated with the severity of diastolic dysfunction,
neurohumoral markers and functional capacity as determined by
Speciﬁc Activity Scale. In their study, late H/M and WR were corre-
lated with functional capacity, as observed in our analysis, which
employed the most accurate values of CPET. The authors [5]
suggested that 123I-MIBG imaging could be a useful tool for risk
stratiﬁcation in HFpEF.
We observed that an altered adrenergic activity is associated
with an inadequate HR response during exercise. This abnormal be-
havior of the HR could be the determinant of a lower peak VO2 in
HFpEF [6,7]. The adrenergic hyperactivity in rest is associated to
the abnormal behavior of HR during exercise due to refractory sym-
pathetic stimulation, and not because of ineffective sympathetic
stimulation [10].
Our sample consisted of patients with HFpEF with low VE/VCO2
slope, which may be a limitation to our study. We believe that this is
due to the fact that our sample consisted of outpatient basis. Despite ashout rate and heart rate reserve.
902 Correspondencelow functional capacity, they were clinically stable. Our data are super-
posed to the lower VE/VCO2 slope values of Guazzi et al. [8] indicating
that our ﬁndings are compatible with stable HFpEF patients. VE/VCO2
slope relatively normal may be explained by a preserved cardiac output
during exercise.
In summary, our data showed an association between severity of
sympathetic neuronal dysfunction and the degree of cardiovascular
impairment during exercise. These ﬁndings suggest that 123I-MIBG im-
aging may contribute to a better understanding of the pathophysiology
and risk stratiﬁcation in HFpEF.
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